We invest in passionate people.

Blacksmith Medicines, a spin-out of Forge Therapeutics, is pioneering a novel metalloenzyme chemistry platform to create new immuno-oncology and inflammation medicines.

San Diego, CA

First Investment
January 2021 | Seed

Capsigen is developing next generation AAV vectors using its proprietary TRADE™ technology, enabling the identification of customized safe and effective vectors that meet disease-specific criteria.

Vancouver, WA

First Investment
December 2020 | Seed

Covagen AG developed next-generation protein drugs for inflammatory diseases and cancer using its proprietary protein engineering technology. Covagen AG was acquired by J&J in 2014.

Zurich, Switzerland

First Investment
October 2009 | Seed

Exit
August 2014 | Acquisition

Draupnir Bio has developed a proprietary platform enabling the targeted protein degradation of extracellular and membrane-bound proteins.

Copenhagen, Denmark

First Investment
March 2024 | Seed

EditForce has developed a proprietary RNA/DNA editing technology using pentatricopeptide repeat (PPR) proteins, applicable to the pharmaceutical, agricultural, and biomanufacturing industries.

Fukuoka, Japan

First Investment
June 2021 | Series C

FerroKin Biosciences developed a next-generation iron chelator for the treatment of iron overload in patients with transfusion-dependent anemia. FerroKin was acquired by Shire Plc in 2012.

San Carlos, CA

First Investment
December 2008 | Series A

Exit
March 2012 | Acquisition

F-star is a clinical-stage company focused on developing bispecific antibody therapeutics. F-star’s lead program is a LAG-3 / PD-L1 bispecific antibody.

Cambridge, UK and Vienna, Austria

First Investment
January 2010 | Series A Extension

Forge Therapeutics uses a novel drug discovery platform to identify and develop first-in-class therapeutics against metalloprotein drug targets.

San Diego, CA

First Investment
April 2017 | Series A

Genkyotex is developing orally available small molecule therapeutics that selectively inhibit NOX enzymes to treat multiple diseases.

Geneva, Switzerland

First Investment
May 2011 | Series C

Exit
April 2014 | IPO

Genocea Biosciences uses its proprietary platform for the rapid discovery of T-cell antigens to develop novel vaccines for oncology and infectious disease.

Cambridge, MA

First Investment
January 2011 | Series B

Exit
February 2014 | IPO

Intradigm Corporation developed RNA interference therapeutics for the treatment of serious diseases, and merged with Silence Therapeutics in December 2009.

Palo Alto, CA

First Investment
September 2008 | Series B

Exit
December 2009 | Merger/IPO

Korro Bio is a leader in RNA-editing therapeutics, using its OPERA technology platform for the treatment of diverse diseases.

Cambridge, MA

First Investment
September 2020 | Series A

LiberoThera is developing new therapeutics targeting membrane proteins including GPCRs using its proprietary membrane protein synthesis technologies.

Tokyo, Japan

First Investment
May 2021 | Series B

miRagen Therapeutics focuses on the discovery and development of innovative microRNA-targeting therapies in disease areas of high unmet medical need.

Boulder, CO

First Investment
November 2015 | Series C

Exit
February 2017 | IPO

Outrun Therapeutics has developed a proprietary platform technology for the identification of therapeutics that selectively target the protein degradation pathway.

Dundee, UK

First Investment
April 2021 | Seed

PharmEnable is unlocking chemical space to develop the next generation of novel, diverse and complex/3D small molecule drugs.

Cambridge, UK

First Investment
November 2022 | Series A

PharmEste s.r.l. developed transient receptor potential (TRP) channel therapeutics for the treatment of neuropathic pain, overactive bladder, and other TRP-mediated diseases.

Milan, Italy

First Investment
September 2008 | Series B

Exit
September 2014 | Closed

Pronota NV was a diagnostics company focused on low abundance protein biomarkers and antibody-free protein assay development. Pronota merged with a division of Biocartis in 2014 to form MyCartis.

Ghent, Belgium

First Investment
October 2009 | Series B

Exit
September 2014 | Merger

QurAlis is focused on the discovery and development of new therapeutics for ALS, targeting excitotoxicity, TBK1 autophagy, and other novel mechanisms.

Boston, MA

First Investment
April 2018 | Seed

Ribometrix has an innovative platform to discover and develop small molecule therapeutics for RNA targets, built on the SHAPE-MaP technology initially developed by its founders.

Durham, NC

First Investment
October 2017 | Seed

Rigontec was a biopharmaceutical company targeting RIG-I for the immune-mediated treatment of cancer and viral diseases. Rigontec was acquired by Merck in 2017.

Bonn, Germany

First Investment
August 2015 | Series A

Exit
September 2017 | Acquisition

SOLA is using its proprietary chaperone platform technology (JUMP70) to develop therapeutics for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Huntington’s disease (HD).

Boston, MA

First Investment
September 2021 | Seed

Sonde is developing a voice-based technology platform to monitor and diagnose psychological and physical medical conditions.

Boston, MA

First Investment
April 2019 | Series A

Syndexa developed novel drugs that targeted the interface between inflammatory and metabolic pathways, using a screening technology to target adaptive ER responses.

Watertown, MA

First Investment
December 2011 | Series B1

Thrasos Therapeutics is a clinical-stage company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease.

Montreal, Canada

First Investment
October 2012 | Series C

TrimTech has developed a novel TPD technology enabling the selective degradation of aggregated proteins involved in neurodegenerative disease.

Cambridge, UK

First Investment
March 2024 | Pre-Seed